Knick B, Thomas L, Vollmar J, Bauer G
Med Klin. 1979 Mar 2;74(9):313-7.
Previous investigations on the effect of beta-receptor blockers on the carbohydrate metabolism of diabetics have reported varying effects, the most frequent being hypoglycaemic symptoms which were interpreted as potentiating effects caused by interference with the antidiabetic agents. For this reason, the effect of the beta-receptor blocker metipranolol on the carbohydrate metabolism of diabetics treated with glibenclamide was investigated in a double blind cross-over study comparing metipranolol with placebo. The results do not show any significant difference between the placebo and the metipranolol with respect to the blood or urinary sugar values or the plasma insulin levels. Whether or not this is a substance-specific property needs to be clarified by further comparative investigations using other beta-receptor blockers. There were similarly no significant differences in the most important parameters of hepatic and renal function.
先前关于β受体阻滞剂对糖尿病患者碳水化合物代谢影响的研究报告了不同的结果，最常见的是低血糖症状，这些症状被解释为与抗糖尿病药物相互作用引起的增强效应。因此，在一项将美替洛尔与安慰剂进行比较的双盲交叉研究中，研究了β受体阻滞剂美替洛尔对接受格列本脲治疗的糖尿病患者碳水化合物代谢的影响。结果显示，在血糖或尿糖值以及血浆胰岛素水平方面，安慰剂与美替洛尔之间没有任何显著差异。这是否是一种物质特异性特性，需要通过使用其他β受体阻滞剂进行进一步的比较研究来阐明。肝肾功能的最重要参数也同样没有显著差异。
